127 related articles for article (PubMed ID: 25716707)
1. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
Innes HA; McDonald SA; Dillon JF; Allen S; Hayes PC; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley AJ; Bramley P; Hutchinson SJ
Hepatology; 2015 Aug; 62(2):355-64. PubMed ID: 25716707
[TBL] [Abstract][Full Text] [Related]
2. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care.
Innes HA; Hutchinson SJ; Allen S; Bhattacharyya D; Bramley P; Delahooke TE; Dillon JF; Forrest E; Fraser A; Gillespie R; Goldberg DJ; Kennedy N; McDonald S; McLeod A; Mills PR; Morris J; Hayes P;
Hepatology; 2011 Nov; 54(5):1547-58. PubMed ID: 22045672
[TBL] [Abstract][Full Text] [Related]
3. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
[TBL] [Abstract][Full Text] [Related]
4. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
5. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
[TBL] [Abstract][Full Text] [Related]
6. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.
van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
J Viral Hepat; 2014 Aug; 21(8):568-77. PubMed ID: 24118177
[TBL] [Abstract][Full Text] [Related]
7. Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model.
Innes H; Goldberg D; Dusheiko G; Hayes P; Mills PR; Dillon JF; Aspinall E; Barclay ST; Hutchinson SJ
J Hepatol; 2014 Jun; 60(6):1118-26. PubMed ID: 24509410
[TBL] [Abstract][Full Text] [Related]
8. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675
[TBL] [Abstract][Full Text] [Related]
9. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
[TBL] [Abstract][Full Text] [Related]
10. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.
Bruno S; Stroffolini T; Colombo M; Bollani S; Benvegnù L; Mazzella G; Ascione A; Santantonio T; Piccinino F; Andreone P; Mangia A; Gaeta GB; Persico M; Fagiuoli S; Almasio PL;
Hepatology; 2007 Mar; 45(3):579-87. PubMed ID: 17326216
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.
Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
J Viral Hepat; 2012 Feb; 19(2):e97-104. PubMed ID: 22239532
[TBL] [Abstract][Full Text] [Related]
12. Long-term cohort study of chronic hepatitis C according to interferon efficacy.
Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911
[TBL] [Abstract][Full Text] [Related]
13. Sex difference in liver-related mortality and transplantation associated with dietary cholesterol in chronic hepatitis C virus infection.
Yu L; Morishima C; Ioannou GN
Br J Nutr; 2016 Jan; 115(2):193-201. PubMed ID: 26541123
[TBL] [Abstract][Full Text] [Related]
14. Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response.
Casado JL; Esteban MA; Bañón S; Moreno A; Perez-Elías MJ; Mateos ML; Moreno S; Quereda C
Dig Dis Sci; 2015 Nov; 60(11):3473-81. PubMed ID: 26112991
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients.
Fernández-Montero JV; Vispo E; Barreiro P; Sierra-Enguita R; de Mendoza C; Labarga P; Soriano V
Clin Infect Dis; 2014 Jun; 58(11):1549-53. PubMed ID: 24633686
[TBL] [Abstract][Full Text] [Related]
16. Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease?
van der Meer AJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):559-66. PubMed ID: 25579804
[TBL] [Abstract][Full Text] [Related]
17. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
Butt AA; Yan P; Shaikh OS; Lo Re V; Abou-Samra AB; Sherman KE
J Hepatol; 2020 Aug; 73(2):277-284. PubMed ID: 32145260
[TBL] [Abstract][Full Text] [Related]
18. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.
Backus LI; Boothroyd DB; Phillips BR; Belperio P; Halloran J; Mole LA
Clin Gastroenterol Hepatol; 2011 Jun; 9(6):509-516.e1. PubMed ID: 21397729
[TBL] [Abstract][Full Text] [Related]
19. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
Backus LI; Belperio PS; Shahoumian TA; Mole LA
Hepatology; 2018 Sep; 68(3):827-838. PubMed ID: 29377196
[TBL] [Abstract][Full Text] [Related]
20. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.
Innes H; McDonald S; Hayes P; Dillon JF; Allen S; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley A; Bramley P; Hutchinson SJ
J Hepatol; 2017 Jan; 66(1):19-27. PubMed ID: 27545496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]